SCHEMBL264367

SCHEMBL264367

CC(=O)c1ccc2cc(Br)ccc2c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.55
MAPT P10636 5/20 0.52
ALDH1A1 P00352 2/20 0.52
HPGD P15428 2/20 0.52
NCEH1 Q6PIU2 1/20 0.47
DHODH Q02127 2/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
MAOB P27338 4/20 0.46
MAOA P21397 2/20 0.45
AKR1C3 P42330 1/20 0.45
AKR1C2 P52895 1/20 0.45
LMNA P02545 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 1/20 0.43
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30350490 1.00 CYP2A6 (0.55) CYP2A6MAPTALDH1A1HPGDNCEH1
SCHEMBL3717349 0.94 CYP2A6 (0.63) CYP2A6MAPTALDH1A1HPGDNCEH1
SCHEMBL14690638 0.90 MAPT (0.66) CYP2A6MAPTALDH1A1HPGDNCEH1
SCHEMBL834744 0.87 CYP2A6 (0.68) CYP2A6MAPTALDH1A1HPGDMEN1
SCHEMBL21215857 0.82 CYP2A6 (0.69) CYP2A6MAPTALDH1A1HPGDMEN1
SCHEMBL15105728 0.82 CYP2A6 (0.69) CYP2A6MAPTALDH1A1HPGDMEN1
SCHEMBL203205 0.81 DHODH (0.55) CYP2A6MAPTALDH1A1HPGDNCEH1
SCHEMBL30020656 0.81 DHODH (0.55) CYP2A6MAPTALDH1A1HPGDNCEH1
SCHEMBL599006 0.80 CYP2A6 (0.79) CYP2A6MAPTALDH1A1HPGDMEN1
SCHEMBL29451111 0.80 CYP2A6 (0.79) CYP2A6MAPTALDH1A1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4519384-B1 PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF PROMEGA CORP (US) 2026-04-29 EP disclosed
US-20250282723-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-09-11 US disclosed
EP-4519384-A1 PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF Promega Corporation (US) 2025-03-12 EP disclosed
EP-4519385-A2 BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING PROMEGA CORPORATION (US) 2025-03-12 EP disclosed
CN-119104641-A Method for detecting impurities of adapalene starting material by utilizing HPLC method 湖北广济医药科技有限公司 2024-12-10 CN disclosed
US-20240191211-A1 BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING PROMEGA CORPORATION 2024-06-13 US disclosed
US-20230357266-A1 PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF PROMEGA CORPORATION 2023-11-09 US disclosed
US-20230357266-A1 PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF PROMEGA CORPORATION 2023-11-09 US disclosed
US-20230357266-A1 PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF PROMEGA CORPORATION 2023-11-09 US disclosed
WO-2023215514-A2 BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING PROMEGA CORPORATION (US) 2023-11-09 WO disclosed
EP-0194579-B1 3-PYRIDYLMETHYLNAPHTHYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS HOECHST AKTIENGESELLSCHAFT (DE) 1991-04-03 EP disclosed
US-4766127-A IMBALANCE WITH PROSTACYCLIN; ANTICOAGULANTS SYNTEX (U.S.A.) INC. (US) 1988-08-23 US disclosed
US-4734406-A 3-pyridylmethylnaphthyl derivatives and composition containing them useful to inhibit thromboxane synthetase HOECHST AKTIENGESELLSCHAFT (DE) 1988-03-29 US disclosed
EP-0194579-A2 3-Pyridylmethylnaphthyl derivatives, process for their preparation and their use as medicaments HOECHST AKTIENGESELLSCHAFT (DE) 1986-09-17 EP disclosed
EP-0137010-A4 NAPHTHYL OR TETRAHYDRONAPHTHYL-SUBSTITUTED NAPHTHOIC ACID AND DE RIVATES. STANFORD RES INST INT (US) 1985-08-12 EP disclosed
EP-0137010-A1 NAPHTHYL OR TETRAHYDRONAPHTHYL-SUBSTITUTED NAPHTHOIC ACID AND DE RIVATES SRI INTERNATIONAL (US) 1985-04-17 EP disclosed
WO-1984003505-A1 NAPHTHYL OR TETRAHYDRONAPHTHYL-SUBSTITUTED NAPHTHOIC ACID AND DE RIVATES STANFORD RES INST INT (US) 1984-09-13 WO disclosed
US-4454341-A ANTITUMOR, SKIN DISORDERS SRI INTERNATIONAL (US) 1984-06-12 US disclosed
US-4447452-A ANTIDIABETIC AGENT AYERST, MCKENNA & HARRISON INC. (CA) 1984-05-08 US disclosed
US-4017313-A Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357266-A1 PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF BTD, HLCS, TYR CYP2A6 626/4885MAPT 2176/4885ALDH1A1 268/4885
US-20250282723-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME CRYAA, IAPP, APP CYP2A6 4681/4885MAPT 21/4885ALDH1A1 4174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.